Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Brian A. Walker, Konstantinos Mavrommatis, Christopher P. Wardell, +36

Blood

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Brian A. Walker, Konstantinos Mavrommatis, Christopher P. Wardell, +36

Leukemia

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Sarah Gooding, Naser Ansari‐Pour, Fadi Towfic, +12

Blood

High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma

Anjan Thakurta, María Ortiz, Pedro Blecua, +12

Blood

Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease

Mike J. Mason, Carolina Schinke, Christine Eng, +38

Leukemia

EngineeringEpigenetic ChangeGeneticsPathologyGene Expression Profiling +20

<i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma

Eileen M. Boyle, Cody Ashby, Ruslana G. Tytarenko, +24

Clinical Cancer Research

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma

Anjan Thakurta, William E. Pierceall, Michael Amatangelo, +2

Oncotarget

Activity of lenalidomide in mantle cell lymphoma can be explained by <scp>NK</scp> cell‐mediated cytotoxicity

Patrick R. Hagner, Hsiling Chiu, María Ortiz, +10

British Journal of Haematology

The location of the t(4;14) translocation breakpoint within the <i>NSD2</i> gene identifies a subset of patients with high-risk NDMM

Nicholas Stong, María Ortiz-Estévez, Fadi Towfic, +7

Blood

EngineeringMixed-phenotype Acute LeukemiaGeneticsGenetic EpidemiologyImmunology +24

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Naser Ansari‐Pour, Mehmet Samur, Erin Flynt, +10

Blood

EngineeringRelapsed/refractory MmPathologyTumor BiologyMyeloid Neoplasia +15